表紙
市場調查報告書
商品編碼
987852

外陰陰道念珠菌用病醫藥品的全球市場:2020∼2027年

Global Drugs for Vulvovaginal Candidiasis Market - 2020-2027

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球外陰陰道念珠菌病醫藥品市場成長的要素中,包含念珠菌症的盛行率的上升,研究開發費增加,及新興市場上未開發的機會。但,發展中的經濟體各國的外陰陰道念珠菌病相關認識的不足,預計妨礙在預測期間內的市場成長。

本報告提供全球外陰陰道念珠菌病醫藥品市場相關調查分析,市場概要,市場成長的影響要素,各市場區隔、各地區的市場規模和與前一年同期比較成長,及主要企業等相關分析。

目錄

第1章 全球外陰陰道念珠菌病醫藥品市場:調查手法、範圍

  • 調查手法
  • 調查目的、範圍

第2章 全球外陰陰道念珠菌病醫藥品市場:市場定義、概要

第3章 全球外陰陰道念珠菌病醫藥品市場:摘要整理

  • 市場明細:各製劑類型
  • 市場明細:各藥物類型
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 全球外陰陰道念珠菌病醫藥品市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球外陰陰道念珠菌病醫藥品市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求
  • 專利趨勢

第6章 全球外陰陰道念珠菌病醫藥品市場:COVID-19分析

  • 市場上Covid-19分析
    • COVID-19前的市場情境
    • 目前市場情境
    • COVID-19後或未來情境
  • Covid-19期間中的價格動態
  • 需求與供給的頻譜
  • 大流行期間中的市場相關的政府舉措
  • 製造商策略性舉措

第7章 全球外陰陰道念珠菌病醫藥品市場:各製劑類型

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各製劑類型
  • 市場魅力指數:各製劑類型
    • 局部
    • 子宮托
    • 口服

第8章 全球外陰陰道念珠菌病醫藥品市場:各藥物類型

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各藥物類型
  • 市場魅力指數:各藥物類型
    • Miconazole
    • Clotrimazole
    • Fluconazole
    • Econazole

第9章 全球外陰陰道念珠菌病醫藥品市場:各終端用戶

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各終端用戶
  • 市場魅力指數:各終端用戶
    • 醫院&診所
    • 藥局

第10章 全球外陰陰道念珠菌病醫藥品市場:各地區

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析(%):各地區
    • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析及與前一年同期比較成長分析(%):各製劑類型
    • 市場規模分析及與前一年同期比較成長分析(%):各藥物類型
    • 市場規模分析及與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析及與前一年同期比較成長分析(%):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第11章 全球外陰陰道念珠菌病醫藥品市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第12章 企業簡介

  • Actavis PLC
    • 企業概要
    • 產品系列、說明
    • 主要的焦點
    • 財務概要
  • Cisen Pharmaceutical
  • Bayer AG
  • Bristol-Myers Squibb
  • Effik SA
  • Kingyork Group
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Mycovia Pharmaceuticals

第13章 全球外陰陰道念珠菌病醫藥品市場:重要考察

第14章 全球外陰陰道念珠菌病醫藥品市場:DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

Candidiasis is an infection caused by a yeast called Candida fungi, among which, the most common is Candida albicans. This fungi normally lives on the skin as well as inside the body, in places such as the throat, gut, mouth, and vagina, without causing any problems. The Candida fungi can cause infections, incase if it grows out of control or if enters into the body, such as the bloodstream or internal organs, including the kidney, brain, or heart. However, the candida infections are hardly ever serious in healthy people. In a fewer cases, it may even spread through other parts of the body if the patient's immune system is not working properly.

The global drugs for vulvovaginal candidiasis market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.

Expecetd increase in the prevalence of candidiasis

Candidemia is one of the commonly bloodstream infections in the US. The average incidence was around 9 per 100,000 people, as per the Centers for Disease Control and Prevention (CDC). The organization has further estimated that around 25,000 cases of candidemia occur in the US each year. However, as per CDC, the incidence of candidemia declined in among infants and elderly people in the US during 2009 to 2012. This decline was due to the changes in prophylaxis guidelines and enhanced infection control practices, such as catheter care and hand hygiene. Though, the incidence of candidemia is expected to slightly increase during the forecast period, backed by the rise in the awareness of symptoms associated with candidemia.

Increasing R&D expenditure and expansion of product pipeline

The market for the fungal disease treatment has led to the introduction of a number of effective and safe antifungal agents. A few of the most effective therapies available in the market includes itraconazole, terbinafine, and fluconazole. The increasing R&D spending by the pharmaceutical companies for the development of advanced product pipeline for anti-infective drugs is one of the major factors augmenting the growth of the antifungal drug industry, which in turn, is expected to escalate the drugs for vulvovaginal candidiasis market. The market players are focusing on the development of effective therapeutic agents in immunocompromised patients to cure systemic fungal infections, including candidemia.

COVID-19 Impact Analysis

A increase in the market value of drugs for vulvovaginal candidiasis is expected in 2020, backed by the rise in the prevalence of invasive candidiasis in patients dealing with COVID-19. This is due to the rise in the healthcare-associated infections (HIAs), including cloodstream infections such as candidiasis, especially in patinets that are admitted to hospitals. Therefore, the demand for drugs for vulvovaginal candidiasis increased amid the COVID-19 pandemic, which in turn, increased the sales of the drug in 2020.

Segment Analysis

Based on the drug type, the drugs for vulvovaginal candidiasis market has been classified into miconazole, clotrimazole, fluconazole, and econazole.

Miconazole segment contributed significant share to the global drugs for vulvovaginal candidiasis market in 2019

Miconazole is a synthetic imidazole antifungal drug that eases the symptoms of candidasis by killing the candida fungus. It is majorly used as an effective treatment for vaginal thrush and fungal infections in other parts of the body. It is an oral gel that is available in the market on a prescription from a doctor; however, it can also be bought in smaller packs from pharmacies, without a prescription. It acts rapidly in relieving symptoms of yeasts, dermatophytes, and gram-positive bacteria, available for topical therapy of skin infections.

Based on the formulation type, the drugs for vulvovaginal candidiasis market has been classified into topical, pecessary, and oral.

Topical lead the market throughout the forecast period

Topical segment led the overall market with a share in 2019. A topical formulation of drugs for vulvovaginal candidiasis is used for the treatment of diseases related to the vaginal yeast, which reduces vaginal itching, pain, and discharge with this condition. The topical drug is an antifungal azole, which functions by preventing the growth of the infection-causing yeast.

Geographical Analysis

Based on geography, the study analyzes the drugs for vulvovaginal candidiasis market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominated the global drugs for vulvovaginal candidiasis market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American drugs for vulvovaginal candidiasis market in 2019. The high awareness regarding the vaginal infection from candida is one of the major factor propelling the growth of the market in the region. Moreover, the key market players are headquartered in the US, such as Pfizer Inc. and Johnson & Johnson Services Inc. are further escalating the growth of the market in North America.

Moreover, Asia Pacific is expected to project the fastest growth rate in the drugs for vulvovaginal candidiasis market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific drugs for vulvovaginal candidiasis market during the forecast period. The expansion of global market players in the Asia-Pacific region due to the rising prevalence of vulvovaginal candidiasis in the region are certain factors that will propel the market growth during the forecast period.

Competitive Landscape

The drugs for vulvovaginal candidiasis market is highly competitive, owing to the large presence of drugs for vulvovaginal candidiasis brands. The key drugs for vulvovaginal candidiasis players include Actavis PLC, Bristol-Myers Squibb, Bayer AG, Effik SA, Cisen Pharmaceutical, Sanofi SA, Kingyork Group, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the drugs for vulvovaginal candidiasis market.

Pfizer Inc.

Overview: Pfizer Inc. is a research-based pharmaceutical company that is engaged in the discovery, development, and marketing of healthcare products, including vaccines and medicines. The company operates its business across two segments, namely Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). The company develops and provides over 170 different vaccines and medicines to the global market.

Product Portfolio: The company's portfolio comprises fluconazole.

Why Purchase the Report?

  • Visualize the drugs for vulvovaginal candidiasis market segmentation composition by formulation type, drug type, end user, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the drugs for vulvovaginal candidiasis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of drugs for vulvovaginal candidiasis market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global drugs for vulvovaginal candidiasis market report would provide access to an approx. 57 market data tables, 54 figures, and 262 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Drugs for Vulvovaginal Candidiasis Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Drugs for Vulvovaginal Candidiasis Market - Market Definition and Overview

3. Global Drugs for Vulvovaginal Candidiasis Market - Executive Summary

  • 3.1. Market Snippet by Formulation Type
  • 3.2. Market Snippet by Drug Type
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Drugs for Vulvovaginal Candidiasis Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Candidiasis
      • 4.1.1.2. Rise in R&D spending
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness regarding vulvovaginal candidiasis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Drugs for Vulvovaginal Candidiasis Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Drugs for Vulvovaginal Candidiasis Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Drugs for Vulvovaginal Candidiasis Market - By Formulation Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type Segment
  • 7.3. Market Attractiveness Index, By Formulation Type Segment
    • 7.3.1. Topical*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Pessary
    • 7.3.3. Oral

8. Global Drugs for Vulvovaginal Candidiasis Market - By Drug Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 8.3. Market Attractiveness Index, By Drug Type Segment
    • 8.3.1. Miconazole*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Clotrimazole
    • 8.3.3. Fluconazole
    • 8.3.4. Econazole

9. Global Drugs for Vulvovaginal Candidiasis Market - By End User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.3. Market Attractiveness Index, By End User Segment
    • 9.3.1. Hospital & Clinics*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Pharmacy

10. Global Drugs for Vulvovaginal Candidiasis Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Drugs for Vulvovaginal Candidiasis Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Drugs for Vulvovaginal Candidiasis Market- Company Profiles

  • 12.1. Actavis PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cisen Pharmaceutical
  • 12.3. Bayer AG
  • 12.4. Bristol-Myers Squibb
  • 12.5. Effik SA
  • 12.6. Kingyork Group
  • 12.7. Sanofi SA
  • 12.8. Teva Pharmaceutical Industries Ltd.
  • 12.9. Johnson & Johnson Services Inc.
  • 12.10. Pfizer Inc.
  • 12.11. Mycovia Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Global Drugs for Vulvovaginal Candidiasis Market - Premium Insights

14. Global Drugs for Vulvovaginal Candidiasis Market - DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us